AU2013343430B2 - 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives - Google Patents

1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives Download PDF

Info

Publication number
AU2013343430B2
AU2013343430B2 AU2013343430A AU2013343430A AU2013343430B2 AU 2013343430 B2 AU2013343430 B2 AU 2013343430B2 AU 2013343430 A AU2013343430 A AU 2013343430A AU 2013343430 A AU2013343430 A AU 2013343430A AU 2013343430 B2 AU2013343430 B2 AU 2013343430B2
Authority
AU
Australia
Prior art keywords
pyrrolidine
compound
formula
carbonyl
carbonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013343430A
Other languages
English (en)
Other versions
AU2013343430A1 (en
Inventor
Ernest Giralt Lledo
Roger PRADES COSANO
Soledad Royo Gracia
Teresa Tarrago Clua
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat de Barcelona UB
Fundacio Privada Institut de Recerca Biomedica IRB
Accure Therapeutics SL
Original Assignee
Universitat de Barcelona UB
Fundacio Privada Institut de Recerca Biomedica IRB
IProteos SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat de Barcelona UB, Fundacio Privada Institut de Recerca Biomedica IRB, IProteos SL filed Critical Universitat de Barcelona UB
Publication of AU2013343430A1 publication Critical patent/AU2013343430A1/en
Application granted granted Critical
Publication of AU2013343430B2 publication Critical patent/AU2013343430B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Epidemiology (AREA)
AU2013343430A 2012-11-12 2013-11-11 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives Active AU2013343430B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12382446.8 2012-11-12
EP12382446.8A EP2730571A1 (en) 2012-11-12 2012-11-12 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
PCT/EP2013/073460 WO2014072498A1 (en) 2012-11-12 2013-11-11 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives

Publications (2)

Publication Number Publication Date
AU2013343430A1 AU2013343430A1 (en) 2015-07-02
AU2013343430B2 true AU2013343430B2 (en) 2017-05-25

Family

ID=47278735

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013343430A Active AU2013343430B2 (en) 2012-11-12 2013-11-11 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives

Country Status (25)

Country Link
US (2) US10125097B2 (OSRAM)
EP (2) EP2730571A1 (OSRAM)
JP (1) JP6203278B2 (OSRAM)
KR (1) KR102151290B1 (OSRAM)
CN (1) CN104903314B (OSRAM)
AU (1) AU2013343430B2 (OSRAM)
BR (1) BR112015010377A8 (OSRAM)
CA (1) CA2890042C (OSRAM)
CY (1) CY1118818T1 (OSRAM)
DK (1) DK2917209T3 (OSRAM)
EA (1) EA028422B1 (OSRAM)
ES (1) ES2621672T3 (OSRAM)
HR (1) HRP20170485T1 (OSRAM)
HU (1) HUE032472T2 (OSRAM)
LT (1) LT2917209T (OSRAM)
ME (1) ME02706B (OSRAM)
MX (1) MX367488B (OSRAM)
NZ (1) NZ709096A (OSRAM)
PL (1) PL2917209T3 (OSRAM)
PT (1) PT2917209T (OSRAM)
RS (1) RS55865B1 (OSRAM)
SI (1) SI2917209T1 (OSRAM)
SM (1) SMT201700202T1 (OSRAM)
WO (1) WO2014072498A1 (OSRAM)
ZA (1) ZA201504269B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2730571A1 (en) 2012-11-12 2014-05-14 Universitat De Barcelona 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
EP3031458A1 (en) * 2014-12-09 2016-06-15 Iproteos S.L. Use of 1-[(2-phenylcycloprop-1-yl)carbonyl]-2-[(1,3-thiazolidin-3-yl)carbonyl]perhydroindole in the treatment of schizophrenia-associated cognitive deficits
IL275333B2 (en) 2017-12-15 2023-09-01 Praxis Biotech LLC Inhibitors of fibroblast activation protein
US11504364B2 (en) 2018-12-21 2022-11-22 Praxis Biotech LLC Inhibitors of fibroblast activation protein
BR112023000335A2 (pt) 2020-07-07 2023-01-31 Accure Therapeutics S L 1-[1-(4-benzilóxi-3,5-diflúor-benzoil)-4-flúor-pirrolidina-2-carbonil]-pirrolidina-2-carbonitrila
MY208099A (en) * 2020-12-28 2025-04-15 Sarawak Biodiversity Council Compound for treating neurodegenerative diseases and its isolation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100081701A1 (en) * 2005-09-02 2010-04-01 David Michael Evans FAP inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0536163A1 (en) * 1990-06-04 1993-04-14 Pfizer Inc. Aromatic pyrrolidine and thiazolidine amides
US6159938A (en) 1994-11-21 2000-12-12 Cortech, Inc. Serine protease inhibitors comprising α-keto heterocycles
HUT76640A (en) * 1995-08-17 1997-10-28 Chinoin Gyogyszer Es Vegyeszet Compounds of pharmaceutical activity cyclic amide derivatives, pharmaceutical compositions containing them, process for producing them and their use
DE19603510A1 (de) 1996-02-01 1997-08-07 Knoell Hans Forschung Ev Die Verwendung von Terrecyclolsäure A und Terrecyclolsäure A-Derivate als neue Inhibitoren der humanen Prolyl-Oligopeptidase
KR100568841B1 (ko) * 2000-07-19 2006-04-10 에프. 호프만-라 로슈 아게 엔도텔린-전환 효소의 억제제로서의 피롤리딘 유도체
FI20011466A0 (fi) 2001-07-04 2001-07-04 Orion Corp Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä, niiden valmistusmenetelmiä ja käyttö
FI20030014A0 (fi) * 2003-01-03 2003-01-03 Orion Corp Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä
FI20031018A0 (fi) 2003-07-04 2003-07-04 Orion Corp Parannus aivovammasta toipumiseen
JP4630192B2 (ja) 2003-09-24 2011-02-09 日本化薬株式会社 プロリルオリゴペプチダーゼ阻害剤
US7667044B2 (en) 2003-11-03 2010-02-23 Probiodrug Ag Compounds for the treatment of neurological disorders
ES2302473B1 (es) 2006-12-22 2009-06-12 Universidad De Barcelona Agente terapeutico para el tratamiento del desorden afectivo bipolar en mamiferos.
US20120053222A1 (en) * 2009-01-23 2012-03-01 Mark Gorrell Novel Metabolic Disease Therapy
EP2730571A1 (en) 2012-11-12 2014-05-14 Universitat De Barcelona 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100081701A1 (en) * 2005-09-02 2010-04-01 David Michael Evans FAP inhibitors

Also Published As

Publication number Publication date
SMT201700202T1 (it) 2017-05-08
ZA201504269B (en) 2016-09-28
ES2621672T3 (es) 2017-07-04
EP2730571A1 (en) 2014-05-14
AU2013343430A1 (en) 2015-07-02
CA2890042C (en) 2021-06-01
US10125097B2 (en) 2018-11-13
KR102151290B1 (ko) 2020-09-03
HUE032472T2 (en) 2017-10-30
US20190084927A1 (en) 2019-03-21
HK1214597A1 (en) 2016-07-29
MX367488B (es) 2019-08-20
ME02706B (me) 2017-10-20
NZ709096A (en) 2018-04-27
US10611727B2 (en) 2020-04-07
BR112015010377A2 (pt) 2017-07-11
JP6203278B2 (ja) 2017-09-27
LT2917209T (lt) 2017-04-25
EP2917209A1 (en) 2015-09-16
BR112015010377A8 (pt) 2018-01-16
CN104903314B (zh) 2018-06-05
PL2917209T3 (pl) 2017-09-29
MX2015005931A (es) 2016-02-05
RS55865B1 (sr) 2017-08-31
WO2014072498A1 (en) 2014-05-15
SI2917209T1 (sl) 2017-05-31
EP2917209B1 (en) 2017-02-08
CY1118818T1 (el) 2018-01-10
HRP20170485T1 (hr) 2017-06-02
PT2917209T (pt) 2017-03-31
EA028422B1 (ru) 2017-11-30
EA201590942A1 (ru) 2015-10-30
DK2917209T3 (en) 2017-04-18
CN104903314A (zh) 2015-09-09
US20160168088A1 (en) 2016-06-16
CA2890042A1 (en) 2014-05-15
JP2015536965A (ja) 2015-12-24
KR20150082634A (ko) 2015-07-15

Similar Documents

Publication Publication Date Title
US10611727B2 (en) 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
KR20160116018A (ko) 보체 매개 질환의 치료를 위한 아미드 화합물
US9868731B2 (en) Indole amide compound as inhibitor of necrosis
EP4178945B1 (en) 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile
HK1214597B (en) 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
RU2841064C1 (ru) 1-[1-(4-бензилокси-3,5-дифтор-бензоил)-4-фтор-пирролидин-2-карбонил]-пирролидин-2-карбонитрил
HK40084881A (en) 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile
HK40084881B (en) 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile
CN119451944A (zh) Prep结合配体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)